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ABSTRACT
Objectives To assess the ability of a previously developed
hybrid physiology-based pharmacokinetic-pharmacodynamic
(PBPKPD) model in rats to predict the dopamine D2 receptor
occupancy (D2RO) in human striatum following administra-
tion of antipsychotic drugs.
Methods A hybrid PBPKPD model, previously developed
using information on plasma concentrations, brain exposure
and D2RO in rats, was used as the basis for the prediction of
D2RO in human. The rat pharmacokinetic and brain physi-
ology parameters were substituted with human population
pharmacokinetic parameters and human physiological infor-
mation. To predict the passive transport across the human
blood–brain barrier, apparent permeability values were
scaled based on rat and human brain endothelial surface area.
Active efflux clearance in brain was scaled from rat to human
using both human brain endothelial surface area and MDR1
expression. Binding constants at the D2 receptor were scaled
based on the differences between in vitro and in vivo systems of
the same species. The predictive power of this physiology-
based approach was determined by comparing the D2RO
predictions with the observed human D2RO of six antipsy-
chotics at clinically relevant doses.
Results Predicted human D2RO was in good agreement with
clinically observedD2RO for five antipsychotics.Models using
in vitro information predicted human D2RO well for most of
the compounds evaluated in this analysis. However, human
D2RO was under-predicted for haloperidol.
Conclusions The rat hybrid PBPKPD model structure, inte-
grated with in vitro information and human pharmacokinetic
and physiological information, constitutes a scientific basis to
predict the time course of D2RO in man.
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CLbev Brain extra-vascular clearance
(passive permeability clearance
across the BBB)





HBSA Human brain endothelial surface area
Kd In vivo receptor equilibrium dissociation
constant
Ki In vitro receptor equilibrium dissociation
constant determined in inhibition study
koff Receptor dissociation rate constant
kon Receptor association rate constant
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SPECT Single-photon emission computed
tomography
INTRODUCTION
In schizophrenia drug therapy and research, dopamine D2
receptor occupancy (D2RO) is often used as a target biomark-
er to quantify the relationship between efficacy and side effects
(1). Several studies suggest that blockade of 65 to 80% of D2
receptors is the key to antipsychotic efficacy for both conven-
tional neuroleptics and novel antipsychotics (2–4). D2RO
higher than 80% increases the risk of adverse effects such as
extra pyramidal symptoms (5). Thus, D2RO has a central role
in antipsychotic drug discovery, drug development and ther-
apy. Target occupancy is important both in early drug discov-
ery, where accurate knowledge of the degree of occupancy
could help to determine the suitability of a drug candidate
for further development, and later in the drug development
process, when target site occupancy measurements can guide
dose selection (6). D2RO is clinically measured using positron
emission tomography (PET) or single-photon emission com-
puted tomography (SPECT) methodology, which are both
expensive and time-consuming. Tools to predict clinical
D2RO in preclinical drug discovery phases are therefore valu-
able. It is well known that current antipsychotics also activate
or antagonize other targets in the central nervous system. For
example, risperidone has a higher affinity for serotonin (5-
HT2A) receptors than for D2 receptors (5). Extensions of this
tool to other receptors would therefore increase the value of
the current translation framework.
Recently, we have reported physiology-based pharmacoki-
netic-pharmacodynamic (PBPKPD) models to characterize
the time course of D2RO and 5-HT2A receptor occupancy
(5-HT2ARO) in rats (7,8). The mechanistic and physiological
basis of these models should potentially allow the prediction of
human PKPD properties using physiological parameters and
prior information from in vitro and in vivo preclinical studies (9).
The present investigation aimed to determine how these
models can be used for translating receptor occupancy from
rat to humans.
Development of a translation tool to predict human D2RO
(based on PKPD models) involves scaling information from
rat to human. This involves accounting for drug distribution
to the brain and the drug’s ability to bind to striatal D2 recep-
tors. Drug distribution to the brain is not only characterized
by passive diffusion but also by active efflux transporters pres-
ent at the luminal surface of the blood–brain barrier (BBB).
Similarities in the in vitro permeability values determined by var-
ious types of experiments provide a basis to integrate and scale
information on passive drug transport to the brain from in vitro
to in vivo or from one species to the other (10). However,
differential expression and limited homology of drug trans-
porters involved in active drug transport across the BBB leads
to challenges when scaling active transport related informa-
tion from one species to another (11). Notwithstanding diver-
gent reports on the species independence of drug-specific pa-
rameters, integration of in vitro parameters with physiologically
based PKPD modeling would increase the potential of suc-
cessfully translating effects from preclinical species to humans
(12).
Hence, the objective of this work was to explore different
approaches to predict human striatal D2RO using a generic
translational PBPKPD model structure, which allows
integration and scaling of information from preclinical in vitro
or in vivo data to the human situation. Different approaches
were compared to determine the minimal amount of
information required for this translational work. A previously
developed extendedmodel structure (8) was also used to predict
human 5-HT2ARO based on these approaches.
METHODS
Data
This work was performed within the framework of the Dutch
Top Institute Pharma project: Mechanism-based PK–PD
modeling (http://www.tipharma.com). This mechanism-
based PKPDmodeling platform involves leading pharmaceu-
tical companies worldwide, and academic institutes from the
Netherlands. Three pharmaceutical companies who are the
members of this mechanism-based PK–PD modeling plat-
form, namely, Janssen Research and Development - Belgium,
Merck Sharp and Dohme - The Netherlands and Pfizer
Worldwide Research and Development – USA, provided hu-
man plasma concentration data for haloperidol (HAL), risper-
idone (RIS) and paliperidone (PAL, in extended release
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formulation) and helped with collection of human D2 and 5-
HT2A receptor occupancy data. Clozapine (CLZ), HAL,
olanzapine (OLZ), RIS, extended release formulation of
PAL and quetiapine (QTP) were used in this study as model
antipsychotic drugs. The observed human D2RO for these
antipsychotics were taken from the literature (2,13–24). For
risperidone (RIS), human D2ROwas provided from the phar-
maceutical companies who are involved in this project.
Population pharmacokinetic (PK) parameters for CLZ,
OLZ, QTP and RIS were obtained from literature
(1,25,26). However, no population PK models have been re-
ported in literature for HAL and PAL. So, for these com-
pounds in-house population PK models were developed.
The population PK model for haloperidol was developed on
the basis of data from 7 studies, comprised of 122 individuals
[healthy volunteers (n= 20) and schizophrenic patients
(n=102)] and 515 plasma concentrations obtained across a
wide dose range of 1 to 60 mg/day administered either as
single or multiple doses. The population PK model for
paliperidone-extended release was developed on the basis of
data from 3 studies, comprised of 870 individuals and 4169
plasma concentrations obtained across a wide dose range of 3
to 15 mg/day administered as an OROS® once daily
formulation.
Physiology-Based PKPD Model Structure
A PBPKPD model was previously developed and evaluated
for its usefulness in describing the time course of brain con-
centration and D2RO in rats (7). This model contains expres-
sions to describe the kinetics in brain-vascular, brain-extravas-
cular, striatum-free and striatum-bound compartments
(Fig. 1). Following administration, drug is transported from
the plasma compartment to the brain-vascular compartment;
this process is assumed to be determined only by the cerebral
blood flow. Only the unbound drug in this vascular compart-
ment crosses the BBB and is transported into the brain-
extravascular compartment, which is governed by the brain-
extravascular clearance (CLbev). Furthermore, drug is
transported from the brain-extravascular compartment to
the striatal-free compartment. The brain-extravascular and
striatum-free compartments were assumed to be equilibrating
rapidly. In striatum-bound compartment, drug can reversibly
bind to the dopamine receptor complex (Fig. 1). The receptor
association and dissociation processes were described using
kon as the receptor association rate constant (nM
−1h−1), koff
Fig. 1 A schematic representation of the PBPKPD model. The model
incorporates different processes to explain the time course of D2RO. The
brain pharmacokinetics describes the processes involved in the transport of
drug from plasma to brain, and the striatum compartment explains the drug
binding to receptors through the binding constants.
b
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as the receptor dissociation rate constant (h−1) and D2 recep-
tor density in striatum (nM).
In addition to the previously developed rat PBPKPD
model structure, an active efflux clearance (CLeff) com-
ponent between brain-extravascular and brain-vascular
compartments was included in this predictive model to
reflect the active drug transport from brain, when ap-
propriate (i.e., for RIS and PAL). Additionally, this rat
PBPKPD model structure was extended to account for
binding of RIS and PAL to the 5-HT2A receptor (8).
This extended model included two additional compart-
ments (cortex-free and cortex-bound). Binding to 5-
HT2A receptors was described using association and dis-
sociation constants and receptor density values specific
for 5-HT2A receptors. This extended model structure
was used to predict both D2 and 5-HT2A receptor oc-
cupancy in humans in this simulation study.
Human D2RO predictions
The rat PBPKPD model structure (Fig. 1) was used to predict
the D2RO versus time profile of antipsychotics in humans by
substituting all parameters of the rat model by their human
analogues, according to the following methods:
(1) Human population PK parameters estimated using total
plasma concentrations were obtained either from models
developed in-house or from published literature (Table
I).
(2) Physiological parameters, such as blood flow to the brain
and the brain volumes were obtained from literature
(Table II).
(3) Passive permeability transport across the BBB was scaled
from in vitro or in vivo rat to in vivo human based on the
assumption that permeability for passive diffusion per
cm2 of brain endothelial surface area is identical the be-
tween different systems.
(4) Active efflux transport for PAL and RIS was scaled using
pertinent information on Pgp protein expression in the
different systems as a scaling factor.
(5) Receptor binding was either derived from in vitro Ki
values or in vivo Kd values corrected for differences be-
tween the in vitro and the in vivo system of the same species.
(6) Experimentally determined values of the fraction un-
bound in human plasma and in rat brain were ob-
tained from the literature. Unbound fraction in hu-
man brain is assumed to be equal to the unbound
fraction in rat brain.
Different approaches were used to obtain human parame-
ters and they were detailed as Approaches A-C in this section.
Approach A was based only on human in vitro information
(in vitro apparent permeability, efflux ratio (ER), in vitroKi
and koff).
Approach B was based on the in vivo parameters (rCLbev,
rCLeff, Kdrat, koff-rat) obtained from the rat PBPKPD
model.
Approach C was aimed at using minimal information to
get the best predictions of human D2RO by integrating
approaches A and B.
All the parameters values used for these simulations are
presented in Table III.
Approach A: HumanD2RO predictions based on in vitro
information
Passive drug transport at the BBB
Experimentally determined in vitro apparent permeability
(Papp) values were used to predict passive transport of anti-
psychotics across the BBB. Specifically, values of the v perme-
ability across multidrug resistance Madin-Darby canine kid-
ney (MDR1-MDCK) type II cell monolayers were obtained
from Summerfield et al. (32). Permeability determined while
attenuating transporters denotes the ability of the molecule to
traverse membranes by passive means (41). These Papp values
were translated to a meaningful parameter of human brain
extra-vascular clearance (hCLbev) across the BBB by taking
the product of Papp and human brain endothelial surface
area of 20 m2 (27).
Passive and active drug transport at the BBB
For the antipsychotics PAL and RIS that are known to
have both active and passive transport across the BBB,
the drug transport component was derived from Papp
and in vitro efflux ratio (ER) determinations. ER is com-
monly used as an indicator of active drug transport in
CNS drug discovery. ER is calculated as the ratio of
effective permeability for a drug from the basal side to
the apical side to that in the opposite direction (37). ER
was used to calculate the human active efflux clearance
(hCLeff) of RIS and PAL. The parameters describing
hCLbev and hCLeff accounting for active transport were
derived based on Kwon et al. (42), underlying deriva-











¼ 2*Papp*HBSA* ER−1ð Þ
ERþ 1 ðEq2Þ
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hCLbev and hCLeff represent the passive permeability and
active transport clearance across the BBB in humans, respective-
ly. Papp represents the in vitro apparent permeability and HBSA
represents human brain endothelial surface area of 20 m2..
Receptor binding parameters
In vitro Kihuman values were used as the parameter Kd (equi-
librium constant). If available, in vitro or ex vivo experimentally
determined koff values were used in these simulations (Table
III). If experimental koff values were not available, then calcu-
lated koff values based on Ki and koff correlation of different
antipsychotics were used, as reported previously (5).
Approach B: Human D2RO predictions based on in vivo
information
The appropriateness of using the available rat hybrid PBPKPD
model to determine in vivo parameters for human D2RO pre-
dictions was assessed. Binding constants (Kon and Koff) and
clearances (rCLbev and rCLeff) were obtained using PBPKPD
models developed by us previously (7,8). This in vivomodel based
information was only available for OLZ, PAL and RIS.
Passive drug transport to the brain
Calculated Papp (Pappcalc) values were derived as the ratio
between PBPKPD model-estimated in vivo rCLbev and rat
brain endothelial surface area (150 cm2/g) and then normal-
ized for an average rat brain weight of 2 g/250 g of rat (32).
The product of Pappcalc and the human brain endothelial
surface area (20 m2) was used as the hCLbev - the passive
transport clearance across the human BBB.
Active drug transport from the brain
Human active efflux clearance was predicted based on the
PBPKPD model-estimated rCLeff and mdr1a protein expres-
sion in micro vessels in mouse. Mdr1a expression values for
rats were not available; hence, mdr1a expression in rat brain
was assumed to be equal to that of mouse. Mouse mdr1a
expression was documented as 14.1 fmol/μg of protein, and
MDR1 expression in human brain was documented as 6.06
fmol/μg of protein (11). The following Eq. (Eq 3) describes the








MDR1 expression in human brain
Mdr1a expression in rat brain
ðEq3Þ
Receptor binding parameters
Model estimated in vivo kon-rat and koff-rat values were used as in
vivo human kon and koff assuming that these drug-specific pa-
rameters do not require any scaling between species (9). For
OLZ, model estimated in vivo Kdrat and koff-rat values were
taken from our previous publication (7). For RIS and PAL,
in vivo binding constants were obtained from the extended
model structure where the time courses for D2 and 5-HT2A
receptor binding were modeled together (8). These parame-
ters are shown in Table IV.
Table I Human Population
Pharmacokinetic Parameters
(Inter-Individual Variability as %
Coefficient of Variation) Used in the
Human D2RO Predictive Model
Clozapine Haloperidol Olanzapine Paliperidone Quetiapine
Vc (L) 719 (62) 401 (37) 1150 (75) 395.4 (47) 380 (10)
CL (L/h) 37.9 (28) 53.0 (44) 19.5 (58) 14.15 (45) 96.0 (59)
Vp (L) – 1500 – – –
Q (L/h) – 140 – – –
F (%) –a 60 –a –a –a
Ka (h−1) 1.37 (24) 0.230 0.600 (32) 2.49 2.50 (80)
DUR (h) – – – 22.87 –
Clozapine, Olanzapine and Quetiapine: Reference (25); Haloperidol and Paliperidone: Parameters obtained from
model developed in-house; Risperidone: Reference (26)
Vc-central volume of distribution, CL-clearance, Vp-peripheral volume of distribution, Q-inter-compartmental clear-
ance, F-absolute bioavailability, Ka-absorption rate constant, DUR- duration of zero-order absorption
a Not estimated and assumed to be 100%
Table II Physiological Values Used in the Human D2RO Predictive Model
Value Reference
Human cerebral blood flow (L/h) 36.0 (27)
Human brain extravascular volume (L) 1.40 (28)
Human brain vascular volume (L) 0.150 (28)
Human striatal volume (L) 0.00700 (29)
Human cortex volume (L) 1.08 (28)
Dopamine D2 receptor density in
human striatum (nM)
28.0 (30)
5-HT2A receptor density in human
frontal cortex (nM)
195 (31)
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Approach C: Human D2RO predictions integrating in
vitro and in vivo information
Passive and active drug transport to the brain
Scaling and calculation used in Approach A were also applied
in the integrated Approach C.
Receptor binding parameters
In vivo Kdhuman parameters were corrected for the differences
between in vitro and in vivo scenarios by normalizing model
estimated in vivoKdrat and in vitroKi values for rat and human,
as shown in Eq. (Eq 4).
K dhuman nMð Þ ¼ InvitroK ihuman* InvivoK dratInvitroK irat ðEq4Þ
In vivo koff-human values were assumed to be equal to in vitro
or ex vivo experimentally determined koff values.
Human 5-HT2ARO predictions
The objective of this exercise was to check the utility of the
extended model structure to predict human D2RO and 5-
HT2ARO. In vitro Kihuman and Kirat for PAL were 0.250 nM
(43). In vitro Kihuman and Kirat for RIS were 0.160 and 0.210
nM, respectively (43,44). We were unable to find koff value for
5-HT2A binding from any in vitro source and so, the in vivo
based Approach B and the integrated Approach C were ap-
plied for these predictions.
Table III In Vitro, In Vivo and Ex Vivo Values Estimates Used in the Human D2RO Predictive Model
Clozapine Haloperidol Olanzapine Paliperidone Quetiapine Risperidone
Fraction unbound in brain 0.011 a 0.023 b 0.034 a 0.0755 c 0.025 a 0.0699 c
Fraction unbound in plasma 0.0300 d 0.0800 e 0.0700 m 0.226 f 0.170 e 0.100 f
Approach A: Human D2RO predictions based on in vitro information
Papp×10−6 (cm/s) 28.3 a 28.6 a 15.7 a 16.8 g 33.0 a 19.8 g
CLbev (L/h) derived from Papp 2.04 2.06 1.13 7.80 2.36 12.96
Efflux Ratio – – – 2.10 g – 1.20 g
CLeff (L/h) based on ER – – – 8.58 – 2.59
In vitro Ki (nM) 82.0 h 0.700 h 5.10 i 2.075 e 155 h 2.175 e
koff (h
−1) 83.16 h 1.02 h 2.34 h 1.56 j,n 180.78 h 1.56 j
Approach B: Human D2RO predictions based on in vivo information
Pappcalc× 10
−6 (cm/s) – – 100 493n – 493
CLbev (L/h) based on Pappcalc – – 72.2 355
n – 355
CLeff (L/h) scaled from rat – – NA 11594 – 2486
koff (h
−1) – – 3.04 k 0.671l,n – 0.671 l
Approach C: Human D2RO predictions integrating in vitro and in vivo information
Corrected In vivo Kd (nM) – – 4.38 0.352 – 0.395
a Reference (32); b Reference (33); c Reference (34); d Reference (35); e In-house values; f Reference (36); g Reference (37); h Reference (38); I Reference
(39); j Reference (5); k Reference (7); l Reference (8); m Reference (40)
NA Not applicable
n Assumed to be equal to risperidone
Table IV Brain PKPD Model Parameter Estimates (% Relative Standard
Error) Obtained from rat PBPKPD Model and Used in the Human D2RO
Predictive Model (Approach B)
Olanzapine a Paliperidone b Risperidone b
CLbev (L/h/kg) 0.433 (16) 2.13
c 2.13 (29)
CLeff (L/h/kg) NA 46.5 (28) 9.97 (28)
Kd (nM) – D2 binding 14.6 (7) 0.463
c 0.463 (14)
koff (h
−1) – D2 binding 3.04 (24) 0.671
c 0.671 (19)
Kd (nM) – 5-HT2A binding NA 0.219
c 0.219 (15)
koff (h




c Assumed to be equal to risperidone
NA Not applicable
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Human D2 receptor occupancy simulations
For each approach (A-C), 1000 human D2RO- time course
curves were simulated at clinically relevant doses, adminis-
tered orally. Differential equations (Appendix 2) explaining
the pharmacokinetics and pharmacodynamics of antipsy-
chotics were used in these simulations as implemented in R
(Version 3.1.0) using the deSolve package (45). Inter-
individual variability (IIV) in the population pharmacokinetic
parameters was accounted for in these simulations. The pre-
dictive power of this translational approach was determined
by comparing these simulations with observed human D2RO.
In clinical trials, human D2RO information were collected
after repeated dosing and at steady state conditions. Hence,
time course of D2RO was simulated and results at steady state
(achieved within 2 or 3 weeks of repeated drug dosing) were
compared with the observed steady state RO.
Predictions of human RO were performed for CLZ
(500 mg/day), HAL (2 mg/day), OLZ (10 mg/day), PAL
(9 mg/day), QTP (750 mg/day) and RIS (4 mg/day) dose
levels and compared graphically with observed D2RO. Addi-
tionally, for OLZ, RIS and PAL box plots of prediction errors
were made to compare the applicability of the different ap-
proaches and their predictive power. For this purpose, D2RO
or both D2RO and 5-HT2ARO predictions were made for a
drug treatment of 3 weeks, at a single time point (12 h after the
last dose of OLZ, RIS and 2 h after the last dose of PAL).
These predictions were then compared with the median of the
actual observations. The selection of dose and time points was
based on the availability of data.
% Prediction Error (PE) was calculated as follows:
%PE ¼ 100* MedianPredictedRO−MedianObservedRO
MedianObservedRO
ðEq5Þ
The median D2RO observed experimentally for OLZ,
PAL and RIS were 54.9, 77.4, 75.8%, respectively. The 5-




This approach predicted the time course of human D2RO
well for five of the antipsychotics, but not for HAL, as depicted
in Fig. 2. The percentage prediction bias of these predictions is
depicted for OLZ, PAL and RIS in Table V and Fig. 3.
Approach B
The predictive model based on in vivomodel estimated param-
eters under-predicted the human D2RO for OLZ, RIS and
PAL (Table V, Fig. 3).
Approach C
The predictive model using the Bcorrected^ in vivo Kdhuman
estimates predicted human D2RO for OLZ are at the best
when compared to the other approaches (Fig. 3). For PAL
and RIS, the D2RO was slightly over-predicted and the pre-
diction bias was large in comparison to Approach A (Figs. 3
and 4) and Table V.
Human 5-HT2ARO predictions
The extended predictive model using the Bcorrected^ in vivo
Kdhuman estimates predicted the human 5-HT2ARO for ris-
peridone better than approach B. Human D2RO predictions
were similar to that of the model which only accounts for the
D2 receptor binding, although the prediction bias for Ap-
proach B is lower (Table V, Fig. 5).
DISCUSSION
This study aimed to utilize the recently proposed rat PBPKPD
model structure (7,8) in a translational framework to scale
pharmacokinetic and pharmacodynamic information from
rats to human. The objective of this work was also to deter-
mine the minimal information required to be included in this
translational framework to predict the D2RO during the early
drug discovery phase, while taking into account distribution to
the brain and receptor binding.
In this simulation study, three approaches (A, B and C)
were used to predict D2RO in human. Approach A uses in-
formation based on in vitro studies, Approach B uses informa-
tion obtained from in vivo studies based on rats and Approach
C integrates both in vitro and in vivo based information. Due to
limitation of in vivo based information, Approach B and Ap-
proach C were applied only for olanzapine, risperidone and
paliperidone. The following part discusses the implementation
of these approaches to translate permeation of drugs to brain
and their binding to D2 receptors.
Translation of passive drug transport at the BBB
It is well known that tight junctions and active efflux trans-
porters present at the luminal surface of the BBB are involved
in the distribution of any substance to the brain. Hence,
hCLbev and hCLeff were included in this model structure to
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explain passive permeability across the BBB and active efflux
processes in a mechanistic manner.
In vitro effective permeability of compounds with various
characteristics across human primary brain endothelial cells
was comparable to those obtained with bovine and rat capil-
lary endothelial cells (10). So, a simplistic way of translation of
passive permeability across the BBB between species is by
accounting for the differences in system-specific brain endo-
thelial surface area and utilize the in vitro effective permeability
information without any scaling between species. In Approach
A, passive permeability of the compounds across the BBB was
calculated as the product of human brain endothelial surface
area and Papp values obtained from in vitro MDR1-MDCK.
Approach B used the passive permeability of compounds
across the BBB under in vivo conditions. This was achieved by
estimating model parameter explaining the passive transport
of drugs across the BBB by fitting a PBPKPDmodel to plasma
and whole brain concentration data obtained from rats.
Pappcalc (permeability across the BBB in vivo) values were de-
rived from PBPKPD model-estimated in vivo rCLbev and rat
brain endothelial surface area.
The hCLbev values calculated based on in vitro Papp or
Pappcalc (calculated based on rCLbev) values were different
(Table III) and this could direct towards a theory on different
efficiency of drug transport in in vitro and in vivo systems. How-
ever, it should be noted that the PBPKPD model-based esti-
mate rCLbev (and thereby Pappcalc) was based on whole brain
concentration and therefore this data do not differentiate the




































































































































Fig. 2 Observed and predicted
steady-state D2 receptor occupancy
in humans after oral administration
of antipsychotics at clinically relevant
doses. Simulations were performed
using the rat PBPKPD model
structure integrated with in vitro
apparent permeability, efflux ratio
and in vitro binding information
(Approach A). Depicted are the
observed D2RO (dots) and the
shaded area represent the 95%
prediction limits of the simulated
D2RO. The medians of the
simulated D2RO are represented as
a solid line.
Table V Prediction Bias (in %) Across Different Approaches Used for
Predicting Human D2RO
Olanzapine Paliperidone Risperidone
Approach A −10 −3 1
Approach B −53 −40 −33
Approach C −4 22 26
Human D2RO using extended model structure
Approach B NA NA −19
Approach C NA NA 25
Human 5-HT2ARO using extended model structure
Approach B NA NA −22
Approach C NA NA −3
NA Not applicable
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influence of the cerebrospinal fluid barrier and other micro-
environment conditions on the transport of drug at the BBB.
In addition, Pappcalc was derived using reported rat brain
endothelial surface area, which ranges from 100 to 240 cm2
per g brain tissue (47,48). These underlying assumptions and
lack of information limited the application of Approach B.
Fig. 4 Observed and predicted
steady-state D2 receptor occupancy
(D2RO) in humans after oral
administration of risperidone or
paliperidone at clinically relevant
doses. Depicted are the observed
D2RO (dots) and the shaded area
represent the 95% prediction limits
of the simulated D2RO. The
medians of the simulated D2RO are
represented as a solid line. Panel (a)
and Panel (b) represent the human
D2RO predictions for paliperidone
achieved by approaches A and C,
respectively. Panel (c) and Panel (d)
represent the human D2RO
predictions for risperidone based on
approaches A and C, respectively.
Fig. 3 Box plots representing the % prediction error (PE) for different ap-
proaches where in vitro, in vivo and integrated in vitro and in vivo information
were used to predict the human D2RO. LettersA,B andC denotes the three
different approaches, Approach A, Approach B and Approach C, respectively.
Fig. 5 Box plots represent the % prediction error (PE) for human D2RO and
5-HT2ARO predictions of risperidone at 4 mg/day dose. % PE for human
D2RO predictions obtained by both D2 model structure (D2MS) and an
extended model structure including 5-HT2ARO (5-HT2AMS) are compared
in the left hand panel. Right hand panel represents the human 5-HT2ARO
predictions of risperidone obtained from the extended model structure using
approach B and C.
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Notwithstanding this limitation, deriving a relationship be-
tween model-estimated rCLbev (and thereby Pappcalc) and in
vitro Papp based on more compounds might help to improve
the translation approach. However, the limited number of
compounds used in our PKPD analysis did not allow us to
elicit such a relationship. So, in the absence of such a relation-
ship, it seems to be more appropriate to base the scaling of in
vitro Papp values to hCLbev on human brain endothelial sur-
face area only. Hence, while integrating in vitro and in vivo
information (i.e., Approach C), the calculated hCLbev was
based only on in vitro Papp value and human brain endothelial
surface area.
Translation of active drug transport at the BBB
Predicting active efflux clearance at the human BBB using in
vitro information was challenging and complicated. In this
simulation study, in vitro ER was used to account for the
active drug transport out of the brain. In Approach A, in
vitro ER was used to calculate the drug transport across the
BBB by means of active transport. Derivation based on Kwon
et al. (42) explains the transport of compound across mem-
branes under in vitro conditions using Papp and ER and by
using this derivation and HBSA, the parameters hCLbev and
hCLeff were calculated for human conditions. This translation
approach is simple and based only on information from in vitro.
Hence, this will be a useful tool to predict brain transport in
human brain environment at early stages of drug develop-
ment. Nevertheless, it should be noted that this translation
approach accounts only for differences in brain endothelial
surface area between species and excludes differences in trans-
porter expression levels. Extension of this approach account-
ing for those differences on microenvironment levels between
different species would help to improve predictions of drug
transport at BBB.
Subsequently, active efflux transport was also scaled to the
human conditions based on the estimates obtained from the
rat PBPKPDmodel parameters and expression of mdr1a pro-
tein in both species (i.e., Approach B). As described earlier,
this PBPKPD model-based estimate of rCLbev (and thereby
Pappcalc) and rCLeff were based on whole brain concentration
and therefore had no ability to differentiate microenviron-
ment conditions at the BBB. In addition, due to non-
availability of the appropriate mdr1a expression data in rats,
it was assumed that it is equal to that of mouse. Additionally,
the active transport was included as a linear process rather
than non-linear as usually described for in vitro systems, since
the free concentrations of drug at the BBB (in rats) were much
lower than the concentrations used in vitro, and remain most
likely below the Km (concentration require for the half -
maximal transport) for the transporter, which makes this as-
sumption acceptable. A proper evaluation of these assump-
tions would help to substantiate the claims, however due to
lack of human brain drug exposure information these assump-
tions are seldom evaluated. Nevertheless, this work provides a
framework to account for the active drug transport in humans.
It is noteworthy that both these approaches (Approach A and
B) are plausible because of their mechanistic basis.
Translation of receptor binding properties
Danhof et al. (49) proposed that the values of drug-specific
parameters such as target affinity are likely to be identical
between species and individuals. This would imply that the
binding rate constants estimated in rats could be used to ex-
trapolate the pharmacodynamics from rat to human. Hence,
it is appropriate to include in vitro or in vivo binding constants in
this model structure to predict human D2RO. This predictive
model structure was obtained from a preclinical system where
the drug binding to D2 receptors was explained by accounting
for the association and dissociation rates of antipsychotics.
The model estimated in vivo Kdrat values for OLZ were close
to in vitro Kirat values (rat cloned D2L system – 17 nM), but in
vitro Kihuman values (human cloned D2L system- 5.1 nM) were
different from both these values of the rat system. Additional-
ly, PAL and RIS in vitroKirat values (most commonly reported
as 2 nM) are different from the model estimated in vivo Kdrat
values (0.364 nM). The human D2RO predictions for OLZ,
RIS and PAL were not consistent with the observed human
D2RO data when model estimated in vivo Kdrat was used as
the in vivo Kdhuman parameter in the predictive model. This
challenges the general belief that drug-specific parameters like
Kd can be used across species without any scaling. However,
this difference between the in vivo and in vitro scenario for the
same species could arise from the assumptions used in both in
vitro calculations and model estimations. Additionally, radio-
ligand selection and disturbances in assumed equilibrium con-
ditions in in vitro and in vivo systems could lead to biased or
inappropriate Ki calculations (50).
Extension of predictive model
It has been demonstrated that the binding to both D2 and 5-
HT2A receptors (extended model) was essential to explain the
relationship between drug exposure and receptor occupancy
in the preclinical system with good precision (8). The model
estimates of in vivo Kdrat for RIS are influenced by the brain
distribution kinetics and it was elucidated that the brain-to-
plasma ratio (in rats) is not constant for RIS, suggesting an
influence of specific binding to receptors on the brain-
kinetics (8). Hence, an extended model structure was used to
predict both D2 and 5-HT2A receptor occupancy in humans.
The extended structure predicted 5-HT2ARO well. Surpris-
ingly, the D2RO predictions achieved by using these two dif-
ferent model structures (D2 alone versus D2 + 5-HT2A)
remained close to each other; and this extension, which was
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essential for model fitting in a preclinical system, did not sig-
nificantly improve the human D2RO predictions (atleast for
Approach C). Nevertheless, this extended model structure un-
derscores the ability of this model framework to be flexible
and extendable to other receptor types.
Our objective was also to study the minimal information
required to predict human D2RO. In general, human D2RO
was predicted well for all compounds except haloperidol when
only in vitro information (Approach A) was used in the simula-
tions. This demonstrates the ability of this model structure to
predict human D2RO with minimal in vitro information.
In this simulation study, the time course of plasma concen-
trations was obtained from available population pharmacoki-
netic parameters. It is also possible to predict these pharma-
cokinetic parameters based on in silico and in vitro information
using commercially available tools, like Simcyp (Simcyp Ltd.,
Sheffield, UK). So, the requirement of population pharmaco-
kinetic parameters obtained from clinical studies is not
essential.
For HAL, D2RO predictions were lower than the observa-
tions. This may be related to the high ratio of unbound con-
centrations of HAL in brain and plasma, which is close to 4 in
rats (51). This high brain to plasma ratio may indicate a
unique active influx transport to the brain. In addition, it
has been documented that the metabolism of HAL involves
a conversion of HAL to reduced haloperidol, and back-
conversion of reduced haloperidol to HAL (52) in the brain
of guinea pigs. Accounting for this metabolism and/or active
influx transport may help to improve predictions. Extending
this predictive model structure to include such complexity is
practically possible, if sufficient information about each relat-
ed process is available beforehand.
Applications of this predictive tool are not limited to only
predicting D2RO in early drug discovery but also in selecting
appropriate first in human doses based on pharmacodynam-
ics. It is not anticipated that predictive tools will completely
replace the need for experiments, though it is plausible that
this tool can help to design more informative and more effi-
cient clinical studies.
CONCLUSION
A general translational framework was developed which
is based on a mechanism-based approach and accounts
for the different processes involved in the transport of
drug to the brain. Based on, in vitro information (Papp,
ER and Ki), the model was able to predict the human
D2RO for drugs distributed to the brain by passive per-
meability and active transport processes. This model
structure with an appropriate extension also predicted
the human 5-HT2ARO well.
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APPENDIX 1
Derivation of the relationship between CLbev, CLeff,
Papp, SA and ER
1. Relationship between CLbev, CLeff, PS and PSpgp
The derivation is based on the model described by Kwon et al.
(42). The model describes the passive and active transport
from the apical side (A) to the basal side (B) of enterocytes. A
similar model was described by Kalvass et al. (53) for various
situations where efflux transporters such as P-glycoprotein
(Pgp) are involved, including the blood–brain barrier.
Equation (Eq 2) of Kwon et al. (42) describes the net change




¼ PS1*CA−PS2*Cent−PSpgp*Cent þ PS4*CB−PS3*Cent
ðA1Þ
where CA and CB are the extracellular concentration at the
apical and basal side, respectively, Cent is the intracellular
concentration, PS1, PS2, PS3 and PS4 are the products of
membrane permeability and surface area for passive transport
from A to intracellular, from intracellular to A, from intracel-
lular to B and from B to intracellular, respectively, and PSpgp
is the product PS for active transport from intracellular to A
by the transporter Pgp.
In situations where the concentrations at both sides A and
B are constant, Cent will be constant, and the net change of M
will be zero. For dM/dt=0, Eq. (Eq 5) can be rearranged and
simplified to:




The net transport over the basal membrane in the direction
from apical to basal side is
N et basal membrane fluxAB ¼ PS*Cent−PS*CB ðA3Þ
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Replacing Cent by Eq. (A1)
N et basal membrane fluxAB ¼






The net transport over the apical membrane in the direc-
tion from apical to basal side is
N et apical membrane fluxAB ¼ PS*CA− PS þ PSBð Þ*Cent ðA5Þ
Replacing Cent by Eq. (A1) yields the same result as Eq.
(A3), since it was assumed that there is no accumulation in the
cells.
The passive diffusion clearance CLbev is defined as the
passive membrane flux from A to B divided by the concentra-





The active efflux clearance CLeff is defined as the efflux by





Equations (A5) and (A6) define the relationship between
the model parameters CLbev and CLeff, and their determi-
nants, PS and PSpgp.
Note that the passive CLbev is dependent on PSpgp. This is
due to the fact that the active efflux lowers the intracellular
concentration Cent, reducing the effective concentration gra-
dient over the basal membrane. As a result, the passive trans-
port is lower compared to the situation in the absence of active
efflux.
2. Efflux Ratio
The Efflux Ratio is defined as the ratio of the transport clear-
ance (CLBA) from B to A if CA=0 and the transport clearance
(CLAB) from A to B if CB=0 (37). From Eqs. (A3), (A5) and
(A6) the following equations can be derived:
EffluxRatio ERð Þ ¼ PS þ PSpgp
PS
ðA8Þ
EffluxRatio ERð Þ ¼ CLbev þ CLeff
CLbev
ðA9Þ
PSpgp ¼ PS* ER−1ð Þ ðA10Þ
CLeff ¼ CLbev* ER−1ð Þ ðA11Þ
From Eqs. (A3) and (A7) it can be derived that the ratio
CA/CB (plasma/brain ratio) at steady state is equal to the
efflux ratio ER.
3. Relationship between Papp and PS
The apparent permeability Papp is determined by measuring
the net flux over the cell layer in the absence of active efflux
(PSpgp=0). In this case Eq. (A3) can simplified to:
Papp is obtained by dividing by the concentration gradient,
after normalizing for surface area (SA):
Papp ¼ PS2*SA ðA13Þ
Or
PS ¼ 2*Papp*SA ðA14Þ
The factor 2 reflects the passage over two membranes in
series.
4. Relationship between CLbev, CLeff, Papp and ER
Combining Eqs. (A5), (A6), (A9), (A10) and (A13) yields the
following equations:
CLbev ¼ 2*Papp*SAERþ 1 ðA15Þ
CLeff ¼ 2*Papp*SA* ER−1ð ÞERþ 1 ðA16Þ
Equations (A14) and (A15) can be used to calculate the
model parameters CLbev and CLeff from the experimentally
obtained values Papp and ER.
APPENDIX 2
PBPKPD model used to predict human D2RO is defined by
the following differential equations:
(A12)
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d Abvð Þ=dt ¼ CLbv=V plasma
 
*Aplasma− CLbv=V bvð Þ*Abv− CLbev=V bvð Þ* f uplasma* Abv þ CLbev=V bvð Þ* f ubrain* Abev
þ CLbev=V bvð Þ* f ubrain* Abev d Abevð Þ=dt
¼ CLbev=V bvð Þ* f uplasma* Abv− CLbev=V bevð Þ* f ubrain* Abev− CLe f f =V bv
 
* f ubrain* Abev− CLst=V bevð Þ* f ubrain* Abevþ
CLst=V st f
 
* f ubrain*Ast f d Ast f
 
=dt
¼ CLst=V bevð Þ* f ubrain*Abev− CLst=V st f
 
* f ubrain*Ast f−kon* f ubrain*Ast f * Bmax−CBð Þ þ ko f f *Astb d Astbð Þ=dt
¼ kon* f ubrain*Ast f * Bmax−CBð Þ−ko f f *Astb
Where,
subscripts plasma, bv, bev, stf, sb represent volume (V) and
amount (A) of drug in plasma, brain-vascular, brain-extravas-
cular, striatum-free and striatum-bound compartments,
respectively;
CLbv, CLbev, CLst represent transport clearance of drug to
brain-vascular, brain-extravascular, striatum-free compart-
ments, respectively;
CLeff represents the active efflux transport clearance of
drug from brain-extravascular compartment;
Bmax is the dopamine D2 receptor density in nM;
CB is the concentration bound to receptor as (Astb/Vstb)/
(MW/1000) in nM;
MW is the molecular weight of the drug;
D2RO is calculated as CB/Bmax*100%.
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